Published: 2021-11-05

Clinical Management Recommendations

Psoriasis Therapy Beyond Biologics

Connor R Buechler, Jesse Veenstra, Linda Stein Gold

Page 568-578


In-Depth Reviews

Original Research

A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics

Jerry Bagel, Yipeng Wang, Paul Montgomery, III, Christian Abaya, Eric Andrade, Courtney Boyce, Tatiana Tomich, Byung-In Lee, David Pariser, Alan Menter, Tobin Dickerson

Page 621-638

Research Letters


COVID Concepts

Brief Articles

Rare Mucosal Lip Atypical Fibroxanthoma Treated with Mohs Micrographic Surgery

Tara Howard, Taraneh Matin, John Howard, Eduardo Weiss Howard

Page 664-666

Diffuse Large B-cell Lymphoma in Bilateral Lower Extremities

Leon Kou, Kevyn Niu, Austin Wong, Aaron Chen, Sid Danesh

Page 672-675

Atypical Targetoid Lesions as the Presenting Sign of Myeloid Sarcoma

Eduardo Adrian Rodriguez, Edward Visnaw, Frank Petr, Huma Siddiqui

Page 676-679

Dermatofibrosarcoma Protuberans Presenting as a Subcutaneous Cystic Nodule

Chris Logas, Austin Dunn, Danielle Lazarra, Justin Rubin, Eli Saleeby, Brad Glick

Page 689-692

Short Communications

Compelling Comments

Poster Presentations from FC21 Dermatology Conference®: Psoriasis

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials

Leon Kircik, Linda Stein Gold, James Del Rosso, Seemal Desai, Brad Glick, Howard Sofen, Anna Tallman, David Rubenstein, Philip Brown

Page s34

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Philip Brown, Leon Kircik, Anna Tallman, Mark Lebwohl

Page s35

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita

Page s37

Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies

Javier Alonso-Llamazares, Melinda Gooderham, Jerry Bagel, John Browning, Zoe Draelos, Kimberly Grande, Adelaide Herbert, Wei Jing Loo, Chih-ho Hong, Mark Lebwohl, Walter Nahm, Kim Papp, David Pariser, Jennifer Soung, Linda Stein Gold, Irina Turchin, Amy Feng, Patrick Burnett, Robert Higham, David Berk

Page s41

Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk

Page s42

Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study

Angela Moore, Javier Alonso-Llamazares, Neal Bhatia, Alim Devani, Michael Bukhalo, Zoe Draelos, Melinda Gooderham, Steve Kempers, Leon Kircik, Kim Papp, David Pariser, Marina Sankeva, Rodney Sinclair, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk

Page s43

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, Mark Lebwohl, David Adam, Javier Alonso-Llamazares, Chih-ho Hong, Steve Kempers, Leon Kircik, Wei Jing Loo, Daniel Stewart, Walter Nahm, Matthew Zirwas, Patrick Burnett, Robert Higham, Lynn Navale, David Berk

Page s44

Mind.Px – Personalized Medicine for Psoriasis Biologic Treatment

Tobin Dickerson, Byung-In Lee, Paul Montgomery, Stephen Boyd, Eric Andrade, Courtney Boyce, Tatiana Tomich, Yipeng Wang

Page s46

Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial

Bruce Strober , Akihiko Asahina, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard Langley, Jonathan Barker, Christopher Cioffi, Nancy Cross, Maggie Wang, Carle Paul

Page s52

Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Andrew Blauvelt, Lars Iversen, Sandy McBride, Melinda Gooderham, Petra Staubach, Paul Yamauchi, Fabienne Staelens, Veerle Vanoorden, Katy White, Paolo Gisondi

Page s53

Atopic Dermatitis

Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Andrew Blauvelt, Anderas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong , Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson

Page s57

COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial

Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky

Page s58

Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis

Andrew Blauvelt, Jean-Philippe Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Hidehisa Saeki

Page s59

Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Lawrence Eichenfeld, Seth Forman, Michael Kuligowski, May Venturanza, Kang Sun, Eric Simpson

Page s63

Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream

Andrew Blauvelt, Jacek Szepietowski, Kim Papp, Eric Simpson, Jonathan Silverberg, Brian Kim, Shawn Kwatra, Michael Kuligowski, May Venturanza, Kang Sun, Leon Kircik

Page s64

Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement

Eric Simpson, Robert Bissonnette, Michael Kuligowski, May Venturanza, Kang Sun, Jonathan Silverberg

Page s67

Acne & Rosacea

Efficacy and Safety of Tazarotene 0.045% Lotion in White Adults with Moderate-to-Severe Acne

James Del Rosso, Linda Stein Gold, Stephen Tyring, William Philip Werschler, Fran Cook-Bolden, George Han, Neal Bhatia, Eric Guenin

Page s70

Improvements in Acne and Skin Oiliness with Tazarotene 0.045% Lotion in Acne Patients with Oily Skin

Emil Tanghetti, Michael Gold, Neil Sadick, Fran Cook-Bolden, Leon Kircik, Linda Stein Gold, Stephen Tyring, James Del Rosso, Eric Guenin

Page s71

Sarecycline: Rapid Improvement of Truncal Acne in Hispanic Male

Angela Moore, Stephen Moore, Luke Moore, Stephen Tyring, Stephen Tyring

Page s73


Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug

Nicholas Bodor, Adam Friedman, Stacy Smith, James Del Rosso, Janet Dubois, Adelaide Herbert, Tory Sullivan, Zakiya Rice, Joe Gorlick, Leon Kircik, Lawrence Green, Brandon Kirsch, Deepak Chadha

Page s74

Pruritus & Prurigo Nodularis

Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis

Brian Kim, Masato Tamari, Lydia Zamidar, Kristine Nograles, Catherine Munera, Joana Goncalves, Emma Guttman-Yassky, Mark Lebwohl

Page s76

Skin Cancer

A comprehensive diagnostic offering workflow increases the rate of actionable results of the 23- and 35-gene expression profile tests for use as ancillary diagnostic tools for difficult-to-diagnose melanocytic lesions

Matthew Goldberg, Jennifer Siegel, Brooke Russell, Jason Rogers, Kyle Covington, Kristen Oelschlanger, Trisha Poteet, Jeffrey Wilkinson , Michael Berg, Katherine Falkowski, Sarah Kurley, Armineh Kajoian

Page s79

Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis

G Martin, B Berman, S Feldman, A Armstrong , M Edwards, S Graziadio, R McCool, M Arber, E Carr, D James, M Chapman-Rounds, E Fumero, M Schuchardt, A Grada

Page s81


Disorders of Pigmentation


Pooled Results of VP-102 Safety and Efficacy in Phase 3 Trials for Molluscum Contagiosum by Fitzpatrick Skin Type (FST)

Elaine Siegfried, Lawrence Eichenfeld, Pearl Kwong, Seemal Desai, Susan Cutler, Cynthia Wilson, Pamela Rumney, Christine Crosby, Jennifer Andres, Mark McBride

Page s91

Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2

Lawrence Eichenfeld, Elaine Siegfried, Pearl Kwong, Susan Cutler, Cynthia Willson, Pamela Rumney, Christine Crosby, Jennifer Andres, Mark McBride

Page s92

Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US

Shari Lipner, Warren Josepth, Tracy Vlahovic, Richard Scher, Phoebe Rich, Mahmoud Ghannoum, Ralph Daniel, Boni Elewski

Page s93

A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis

Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk

Page s94